

Disclaimer and notes



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES OR TO "US PERSONS" (AS DEFINED IN REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT")) OR INTO OR WITHIN AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN. RECIPIENTS OF THIS DOCUMENT AND THE PRESENTATION (THE "MATERIALS") IN JURISDICTIONS OUTSIDE THE UK SHOULD INFORM THEMSELVES ABOUT AND OBSERVE ANY APPLICABLE LEGAL REQUIREMENTS IN THEIR JURISDICTIONS. IN PARTICULAR, THE DISTRIBUTION OF THE MATERIALS MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS. ACCORDINGLY, RECIPIENTS REPRESENT THAT THEY ARE ABLE TO RECEIVE THE MATERIALS WITHOUT CONTRAVENTION OF ANY APPLICABLE LEGAL OR REGULATORY RESTRICTIONS IN THE JURISDICTION IN WHICH THEY RESIDE OR CONDUCT BUSINESS.

The information presented herein is not an offer for sale within the United States of any equity shares or other securities of Apax Global Alpha Limited ("AGA"). AGA has not been and will not be registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition, AGA's shares (the "Shares") have not been and will not be registered under the Securities Act or any other applicable law of the United States. Consequently, the Shares may not be offered or sold or otherwise transferred within the United States, or to, or for the account or benefit of, US Persons, except pursuant to an exemption from the registration requirements of the Securities Act and under circumstances which will not require AGA to register under the Investment Company Act. No public offering of the Shares is being made in the United States.

This document represents the quarterly report of AGA. It does not constitute an advertisement and is not a prospectus. It does not constitute an offer to sell or a solicitation of an offer to buy any securities described herein in the United States or in any other jurisdiction, nor shall it, by the fact of its distribution, form the basis if, or be relied upon, in connection with any such contract. No offer, invitation or inducement to acquire Shares or other securities in AGA is being made by, or in connection with, this document.

The information and opinions contained in this document are for background purposes only, do not purport to be full or complete and do not constitute investment advice. Subject to AGA's regulatory requirements and responsibilities, no reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness and no representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this document by AGA or any of its affiliates and no liability is accepted by such persons for the accuracy or completeness of any such information or opinions. This information is not intended to provide, and should not be relied upon for accounting, legal, tax advice or investment recommendations. You should consult your tax, legal, accounting or other professional advisors about the issues discussed herein. The descriptions contained herein are summaries and are not intended to be complete and neither AGA nor any of its affiliates undertakes undertakes do undertake any obligation to update or correct any errors or inaccuracies in any of the information presented herein. The information in this document and any other information discussed at the presentation is subject to change. This document does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase any investment nor shall it, or the fact of its distribution, form the basis of, or be relied on in connection with, any contract thereof.

The Materials may include forward-looking statements. The words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding AGA's intentions, beliefs or current expectations concerning, among other things, AGA's results of operations, financial condition, liquidity, prospects, growth and strategies. The forward-looking statements in the Materials are based on numerous assumptions regarding AGA's present and future business strategies and the environment in which AGA will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of AGA to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond AGA's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as AGA's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which AGA operates or in economic or technological trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. AGA expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements to reflect any change in AGA's expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based after the date of the Materials, or to update or to keep current any

Note this presentation covers the period from 1 January 2018 to 31 March 2018 unless otherwise indicated.

The contents of this Presentation, which have been prepared by and are the sole responsibility of the Company, have been approved by Apax Partners LLP solely for the purposes of section 21(2)(b) of the Financial Services and Markets Act 2000, as amended (the "FSMA").

This Presentation is not intended to be marketing as defined in an EU jurisdiction under the EU's Alternative Investment Fund Managers Directive (2011/61/EU).

Date: 2 May 2018

Financial Highlights

Broadly flat performance in a volatile market environment



Total NAV Return¹ 1Q18 / 1Q18 constant currency

 $(0.7\%)/1.0\% \ 0.0\%/1.3\%$

Total Return – Private Equity² 1Q18 / 1Q18 constant currency

Total Return – Derived Investments² 1Q18 / 1Q18 constant currency

Highlights in 1Q18

 1.0% Total NAV Return on a constant currency basis. Significant FX impact as the euro strengthened by 2.6% against the US dollar resulting in a Total NAV Return of negative 0.7%

Adjusted NAV³ at 31 March 2018

€883.3m/ £776.5m

Adjusted NAV per share at 31 March 2018

Dividends per ordinary share paid in respect of 2H17 (€/£)

€1.80/£1.58 4.73c/4.17p

- Constant currency Total Return of 1.3% in Private Equity and 1.3% in Derived Investments
 - 0.6% constant currency Total Return in Derived Debt (-1.7% actual)
 - 2.4% constant currency Total Return in Derived Equity (-0.2% actual)
- Adjusted NAV per share of €1.80, down from €1.86 at 31 December 2017. Dividend payments and adverse FX movements offset investment gains
- Dividend of 4.73c in respect of 2H17 was paid in 1018

Market capitalisation at 31 March 2018

€726.2m/ £638.4m

Percentage of funds invested at 31 March 2018

Portfolio split at 31 March 2018

Private Equity: Derived Investments

 AGA was 97% invested at 31 March 2018 with the portfolio skewed towards Private Equity

^{1.} Total NAV Return means the movement in the Adjusted NAV per share over the period plus any dividends paid. Adjusted NAV per share used in the calculation is rounded to five decimal points

Total Return reflects the sub-portfolio performance on a stand-alone basis


Adjusted NAV represents NAV of €883.3m adjusted for the estimated performance fee reserve of €Nil at 31 March 2018

Source: Bloomberg

Adjusted NAV development and performance




Even contribution from all asset classes, offset by FX movements and dividends paid



Highlights

- Adjusted NAV decreased by €29.1m mainly due to dividend payments of €23.5m and adverse FX effects of €14.8m
- Income and fair value gains of €8.9m contributed positively with contributions from both Private Equity and Derived Investments
 - Income of €4.8m was mainly earned from the Derived Debt portfolio



- Excluding FX, both Private Equity and Derived Investments contributed positively to performance
 - Private Equity contribution: 0.4%
 - Derived Investments contribution: 0.6%
- FX movement mainly driven by the euro appreciating 2.6%³ against the US dollar during the year with negative impact of 1.7% on Total NAV Return
- AGA does not employ a currency hedging strategy

^{1.} See slide 24 in the appendix for details regarding NAV per share data


^{2.} Performance fee adjustment accounting for the movement in estimated performance fee reserve payable of €Nil at 31 March 2018

^{3.} Source: Bloomberg

AGA invested portfolio at 31 March 2018







^{1.} Excludes cash and cash equivalents and net current assets, including these the NAV is €883.3m. Adjusted NAV excludes the estimated performance fee of €Nil and is €883.3m at 31 March 2018

 ¹Q18 / 1Q18 Total Return on a constant currency basis
 Distributions of €7.0m from AIX, of which €5.6m was return of calls; €4.8m from AVIII; €1.6m from AEVII and €0.4m from AMI



Private Equity Adjusted NAV development and performance



Portfolio relatively static with €13.8m of distributions





Highlights


- Distributions from AIX of €7.0m, of which €5.6m was a return of a call, divestments in Apax VIII of €4.8m, AEVII of €1.6m and AMI of €0.4m
- Unrealised gains contributed €3.2m or 0.6% to performance, driven mainly by organic growth of the underlying portfolio companies in the Apax Funds
- Largest absolute fair value gains:
 - ThoughtWorks (+€2.8m, current NAV³: €19.2m)
 - GlobalLogic (+€2.4m, current NAV³: €32.2m)
 - Azelis (+€2.1m, current NAV³: €57.9m)
- Largest mark-downs:
 - EVRY (-€2.8m, current NAV³: €23.6m)
 - Quality Distribution (-€2.2m, current NAV³: €15.4m)
 - Syneron Candela (-€1.9m, current NAV³: €10.0m)
- FX movement mainly due to the appreciation of the euro against the US dollar by 2.6%⁴
 - 44% of AGA's PE portfolio is denominated in US dollars

- 1. Performance fee adjustment accounting for the movement in the estimated performance fee reserve of €Nil at 31 March 2018
- 2. Includes AGA's exposure to carried interest holdings in Apax Europe VII which was valued at €20.2m at 31 March 2018
- 3. Current NAV represents AGA's gross indirect look-through NAV in the Apax Funds at 31 March 2018
- 4. Source: Bloomberg

Private Equity valuation drivers

Market downturn affecting valuation multiples





Highlights

- Growth in underlying earnings contributed 4.5% to Total Return from organic growth and M&A activity
- Net debt remained relatively stable reducing Total Return by only 0.4%
- Valuation multiples decreased, reducing Total Return by 3.4% reflecting stock market volatility at the end of 1Q18

- FX reduced Total Return by 1.3% as the euro continues to strengthen against the US dollar
- One-off and other reflects amongst others an increased shareholding of the Apax Funds in an existing portfolio company
- Management fees and carried interest accruals at the level of the Apax Funds reduced return by 0.5% in 1Q18

^{1.} Represents movement in all instruments senior to equity

^{2.} Movement in the valuation multiples captures movement in the comparable companies valuation multiples. In accordance with International Private Equity and Venture Capital Valuation ("IPEV") guidelines, the Apax Funds use a multiples based approach where an appropriate valuation multiple (based on both public and private market valuation comparators) is applied to maintainable earnings, which is often but not necessarily represented by EBITDA to calculate Enterprise Value


^{3.} Performance fee adjustment accounting for the movement in the estimated performance fee reserve at 31 March 2018

Private Equity operating metrics












Highlights

- LTM revenue growth strong at 12.9% on average.
 Adjusting for significant M&A, revenue growth was 8.7% in 1Q18 compared to 8.8% in 4Q17
- LTM EBITDA growth slowed from 17.9% to 14.8%.
 Excluding the impact of significant M&A, LTM EBITDA growth was 8.2% in 1Q18 compared to 12.8% in 4Q17
- The average leverage level of portfolio companies remains reasonable at 4.2x LTM EBITDA







March 2018
 December 2017
 Number of investments within the associated band

Note: These operational metrics represent a snapshot of the portfolio as at period end, hence they do not capture the performance of exited investments in the reporting period

- 1. At March 2018 and December 2017 nine investments were respectively excluded as they were financial services companies often valued on book value, growth investments where EBITDA multiples are not relevant or for which clean earnings financials are not available e.g. complex carve-outs, recent acquisitions or write-offs.
- 2. New closed investments in 1Q18 see slide 10 for full list of acquisitions
- Represents investments fully exited in 1Q18 see slide 10 for a full list of disposals

Private Equity activity in 1Q18



ADF adding to its young portfolio, and a strong exit for AEVII and AVIII – Gross IRR: 32%

Acquisitions ¹					
Closed ¹		Cost ²	Announced ¹		Estimated cost ²
WIZELINE	High growth product innovation and digital transformation-focused IT services provider (ADF, North America, Digital)	€1.4m	VYOICE	<u>A follow-on investment</u> : Respiratory devices and consumables manufacturer (AVIII, North America, Healthcare)	c.€8.3m

Divestments Closed – full						Divestmer Partial exi	nts ts, IPO's and others				
			Initial year of purchase	Gross MOIC ⁴	Gross IRR ⁴				Initial year of purchase	Gross MOIC ⁴	Gross IRR ⁴
genex.	Provider of cost containment services to the workers' compensation, disability and auto industries (AEVII & AVIII, North America, Healthcare)	Fully exited	2014	(2.8x)	32%)	⑤	Huarong, a Chinese asset management company (AEVII & AVIII, China, Services)	Recapitalised	2014	(1.3x)	9%)

^{1.} Wizeline closed in March 2018, Vyaire signed in February 2018

^{2.} Cost is AGA's indirect exposure to the underlying portfolio companies held by the Apax Funds. Costs may change following final close of the deal

^{3.} Genex sale closed in March 2018


^{4.} Performance as at 31 March 2018, including unrealised value and total realised proceeds. Calculated since the initial purchase date of the investment. Gross MOICs and Gross IRRs represent return to the fund which invested the most across all Apax Funds into the deal. AVIII-EUR and AIX-EUR shown for AVIII and AIX performances



Derived Investments Adjusted NAV development and performance




Derived Equity continued to produce more attractive deal flow



Highlights

- Adjusted NAV decreased by €18.4m to €288.8m
- €50.9m was invested with €6.0m into one debt investment and €44.9m in to five equity positions²
- Realisations of €76.8m consisted of €53.8m from five Derived Debt realisations and €23.0m from four Derived Equity realisations³
- FX reduced returns as the euro continued to strengthen against major currencies. 88% of AGA's Derived portfolio is held in currencies other than the euro
- Performance fee paid of €15.4m in respect of 2017 was offset by a negative unrealised reserve of €2.1m and had a 0.7% effect on performance




- Return before FX of 1.3%, with income of 1.7% and fair value gains of 0.3%
- Largest gains⁴:
 - Vipshop (+€4.7m, current NAV: €17.3m)
 - Sinopharm Group (+€1.6m, current NAV €14.4m)
 - Talend (+€1.4m, sold in 1Q18)
- Largest mark-downs⁴:
 - Sophos (-€3.5m, current NAV: €11.7m)
 - Strides (-€3.2m, current NAV: €10.9m)
 - Development Credit Bank (-€2.6m, current NAV: €9.3m)

- 1. Performance fee adjustment accounting for the movement in the estimated performance fee reserve at 31 March 2018
- 2. One new debt investment in Genex; four new equity positions in Civitas Solutions, Dignity, Mitie and Greencore and one add-on position in Repco Home Finance
- 3. Five debt realisations comprise of three full exits: one debt position that was called and two sold positions; and two partial realisations. Four equity positions comprise of three full disposals and one partial realisation
- 4. Absolute fair value gains and mark-downs calculated by taking the unrealised fair value movements, realised gains, FX and income earned in 1Q18

Derived Investments Adjusted NAV development and performance




Strong income flow from Derived Debt and gains from Derived Equity exits



Derived Debt

- Constant currency return was flat of 0.6% with strong flow of income and some realised gains offset by a performance fee adjustment and unrealised losses
- Unrealised losses driven by FullBeauty
- FX movements were seen in the Derived Debt portfolio due to the large exposure (92%) to US dollar denominated debt



Derived Equity

- Largest positive driver contributing 2.4%, was from realised gains. All exited positions contributed positively to performance
- Unrealised losses of €1.1m were mainly due to markdowns in Sophos, Strides and Development Credit Bank. These mark-downs were partially offset by gains in Vipshop and Sinopharm Group
- FX continued to negatively impact returns

^{1.} Performance fee adjustment accounting for the movement in the estimated performance fee reserve payable at 31 March 2018


Derived Investments operating metrics






Derived Debt:








Derived Equity:







Highlights

Derived Debt:

- Average LTM EBITDA growth increased to 12.7% for Derived Debt investments mainly due to the exit of one position which had lower EBITDA growth and a significant increase in LTM EBITDA growth noted in two positions
- All Derived Debt had a yield to maturity in excess of 8%

Derived Equity:

- Average LTM earnings were 7.0% for Derived Equity.
 Decrease was mainly due to the addition of four new positions, of which three were slower growing positions
- The average price-to-earnings multiple for the Derived Equity portfolio decreased to 23.3x reflecting addition of slower growing positions

■ March 2018 ■ December 2017

Number of investments within the associated band

Note: These operational metrics represent a snapshot of the portfolio as at period end, hence they do not capture the performance of exited investments in the reporting period

- 1. Gross Asset Value weighted average of the respective metric across the Derived Investments Debt portfolio
- 2. Gross Asset Value weighted average of the respective metric across the Derived Investments Equity portfolio. (Cengage, Answers and Rue21 have been excluded from the analysis above)
- Gross Asset Value weighted average of the current full year income (annual coupon/clean price as at the respective date) for each debt position in the Derived Debt portfolio as at the respective date
- 4. New closed investments in the 1Q18 See slide 15 for full list of acquisitions (inclusive of an add-on position)
- 5. Represents full exits during 1Q18- See slide 15 for list of disposals

Derived Investments transactions in 1Q18



Good flow of realisations from both debt and equity investments – Average Gross IRR: 9.1%

Acquisitions Debt		Cost ¹	Debt Closed –	fully exited			
genex.	Provider of cost containment services to the workers' compensation, disability and auto				Initial year of purchase	Gross MOIC ³	Gross IRR ³
9CHOX.	industries (North America, Healthcare, second lien)	€6.0m	genex.	Provider of cost containment services to the workers' compensation, disability and auto industries (North America, Healthcare,	2014	1.4x	13%
Acquisitions Equity		Cost ¹		second lien)			
Equity		COST	MISYS FINANCIAL SOFTWARE	Provider of financial services software (Europe, Tech & Telco, second lien)	2017	1.0 x	(-6%)
SCIVITAS SOLUTIONS	Provider of health and human services to patients with intellectual disabilities (North America, Healthcare)	€9.0m	RIEMSER ~	German based speciality pharmaceutical company (Europe, Healthcare, first lien)	2017	1.1x	27%
Dignity*	UK funeral services provider (UK, Services)	€8.1m	Equity Closed –	fully exited			
SERVICES	A leading international producer of convenience				Initial year of purchase	Gross MOIC ³	Gross IRR ³
greencore	foods (Europe, Consumer)	€11.4m	🛆 Altair	Product design and development, engineering software and cloud computing software company (North America, Tech & Telco)	2017	1.9x	1883%
mitie	Facilities management company (UK, Services)	€8.5m		China Cinda Asset Management, a Chinese merchant bank and asset management company (China, Services)	2015	0.8x	-9%
Repco Home Finance - We value your Dream	House financing company ² (India, Services)	€7.9m	⇒talend	Open source SaaS provider of data management solutions (North America, Tech & Telco)	2017	1.2x	36%

- 1. Represents the cost acquired during 2018
- 2. Add-on position
- 3. Calculated since the initial purchase date of the investment

Conclusions and Outlook



1Q18 summary

- Total NAV Return was -0.7% and 1.0% on a constant currency basis in a volatile market environment
- Private Equity portfolio with sound operational performance and a constant currency Total Return of 1.3%: LTM EBITDA growth of 14.4%. Average leverage of 4.3x
- Derived Investments with constant currency Total Return of 1.3%
- Second interim dividend of 4.17p in respect of 2H17 was paid on 4 April, equivalent to 2.5% of NAV at 31 December 2017

Private Equity outlook

- Private Equity remains attractive on a relative basis compared to other asset classes
 - Active management of strategic and operational improvements can allow portfolio companies to mature into their high valuations
- Apax VIII and AIX performing well operationally, setting the foundation for value growth
- New deal activity more muted compared to 2017 as valuations in private markets remain high

Derived Investments outlook

- In Derived Debt:
 - Loans remain more attractive than high yield
 - Continue to seek out opportunistic/idiosyncratic/value oriented assets which are under-rated by the market
- In Derived Equities the focus remains on relative value in developed markets and opportunities in emerging markets





The Company

Apax Global Alpha Limited



Manager

The Investment

Apax Guernsey Managers Limited

The Investment Adviser

Apax Partners LLP



About AGA

AGA is a closed ended investment company that invests in a diversified portfolio of Private Equity Investments and Derived Investments in debt and equities.

The Company was admitted to trading on the Main Market of the London Stock Exchange on 15 June 2015.

On 18 September 2017, the Company became part of the FTSE All-Share and Small-Cap Indices.

Ticker: APAX

About AGML

AGA has appointed Apax Guernsey Managers Limited ("AGML" or the "Investment Manager") as its discretionary Investment Manager. AGML is managed by a board of experienced investment professionals and operational private equity executives.

About Apax Partners

Apax Partners LLP is a leading global private equity advisory firm and acts as Investment Adviser to AGML. It operates globally and has more than 30 years of investing experience.

Apax Partners has raised and advised funds that total over €42bn in aggregate at 31 March 2018.

What AGA does

- > Set business objectives and investment strategy
- > Governance and risk management
- > Appointment and oversight of Investment Manager and other service providers

What AGML does

- > Discretionary portfolio management
- > Investment and divestment decisions
- > Portfolio performance analysis and risk management

What Apax Partners do

- > Identification and due diligence of investment opportunities
- > Recommendation of potential investments and divestments to AGML for consideration

The Investment Adviser

Apax Partners



Industry leader

Over €42 billion equivalent of funds raised to date

Pioneer in Private Equity

Established in 1969 in the US and 1972 in Europe¹

Significant global reach


8 offices in 7 countries

Deep bench of industry specialists

c.120 investment professionals


Industry focused investments





Source: Apax Partners internal data







Top 30 Private Equity Investments at 31 March 2018

Private Equity Portfolio (look-through basis) — AGA's indirect exposure

		Fund	Geography	Sector	Valuation €m	% of NAV
1.	Azelis	AVIII	Europe	Services	57.9	7%
2.	Assured Partners	AVIII	North America	Services	50.3	6%
3.	Exact	AVIII	Europe	Tech & Telco	34.0	4%
4.	GlobalLogic	AVIII	North America	Tech & Telco	32.2	4%
5.	Engineering	AVIII	Europe	Tech & Telco	30.4	3%
6.	Unilabs	AEVI & AIX	Europe	Healthcare	29.0	3%
7.	Idealista	AVIII	Europe	Consumer	27.8	3%
8.	EVRY*	AVIII	Europe	Tech & Telco	23.6	3%
9.	Wehkamp	AVIII	Europe	Consumer	20.2	2%
10.	Vyaire Medical	AVIII	North America	Healthcare	19.3	2%
11.	ThoughtWorks	AIX	North America	Tech & Telco	19.2	2%
12.	Cole Haan	AVIII	North America	Consumer	18.8	2%
13.	NuPharm	AVIII	Europe	Healthcare	17.7	2%
14.	Duck Creek Technologies	AVIII	North America	Tech & Telco	16.2	2%
15.	MATCHESFASHION. COM	AIX	United Kingdom	Consumer	15.9	2%
16.	Acelity	AEVII	North America	Healthcare	15.8	2%
17.	Quality Distribution*	AVIII	North America	Services	15.4	2%

Private Equity Portfolio (look-through basis) – AGA's indirect exposure (ctd)

		Fund	Geography	Sector	Valuation €m	% of NAV
18.	Shriram City Union	AVIII	India	Services	14.8	2%
19.	Safetykleen*	AIX	United Kingdom	Services	13.2	1%
20.	Syneron Candela	AIX	North America	Healthcare	10.0	1%
21.	ECi*	AIX	North America	Tech & Telco	9.4	1%
22.	Guotai Junan Securities	AIX	China	Services	8.1	1%
23.	Psagot	AEVII	Israel	Services	7.8	1%
24.	Tivit	AEVI & AEVII	Rest of World	Tech & Telco	7.7	1%
25.	Tosca	AIX	North America	Services	7.0	1%
26.	One Call	AEVII & AVIII	North America	Healthcare	6.8	1%
27.	Attenti	AIX	Israel	Tech & Telco	6.7	1%
28.	Boats Group	AIX	North America	Services	6.6	1%
29.	Zensar Technologies	AVIII	India	Tech & Telco	6.6	1%
30.	Kepro	AIX	North America	Healthcare	6.2	1%
	Total top 30 - gro	ss values			554.6	63%
	Other (other inves	stments, c	arried interest, faci	ility & NCA's)	17.9	2%
	Total Private Equi	ty			572.5	65%

^{*} Denotes overlap with the Derived Investments portfolio



Derived Investments at 31 March 2018

	Derived Inv	estments Port	folio			
		Instrument	Geography	Sector	Valuation €m	% of NAV
1.	KRKA	Listed equity	Europe	Healthcare	20.0	2%
2.	Syncsort	2L term loan	North America	Tech & Telco	20.0	2%
3.	Vipshop	Listed equity	China	Consumer	17.3	2%
4.	Quality Distribution*	2L term loan	North America	Services	16.2	2%
5.	Aptos*	1L term loan	North America	Tech & Telco	15.8	2%
6.	Sinopharm Group	Listed equity	China	Healthcare	14.4	2%
7.	ECi*	2L term loan	North America	Tech & Telco	12.2	1%
8.	Sophos*	Listed equity	United Kingdom	Tech & Telco	11.7	1%
9.	Rentpath	2L term loan	North America	Tech & Telco	11.6	1%
10.	Safetykleen*	2L term loan	United Kingdom	Services	11.2	1%
11.	Greencore	Listed equity	Europe	Consumer	11.0	1%
12.	Strides Shasun	Listed equity	India	Healthcare	10.9	1%
13.	Development Credit Bank	Listed equity	North America	Services	9.3	1%
14.	Dignity	Listed equity	United Kingdom	Services	9.3	1%
15.	Repco Home Finance	Listed equity	India	Services	9.3	1%
16.	Civitas Solutions	Listed equity	North America	Healthcare	9.3	1%
17.	Mitie	Listed equity	United Kingdom	Services	8.8	1%

	Derived Invest	tments Portfo	olio (ctd)			
		Instrument	Geography	Sector	Valuation €m	% of NAV
18.	FullBeauty*	2L term loan	North America	Consumer	8.6	1%
19.	Vertafore	2L term loan	North America	Tech & Telco	8.3	1%
20.	Legal Zoom	2L term loan	North America	Services	8.3	1%
21.	PDC Brands	2L term loan	North America	Consumer	8.2	1%
22.	Advantage Sales & Marketing	2L term loan	North America	Consumer	7.9	1%
23.	TAKE Solutions	Listed equity	India	Tech & Telco	6.1	1%
24.	Genex	2L term loan	North America	Healthcare	6.0	1%
25.	Answers	Equity	North America	Services	5.9	1%
26.	EVRY*	Listed equity	Europe	Tech & Telco	3.8	0%
27.	Rue21	Term Loan & Equity	North America	Consumer	3.8	0%
28.	Cengage Learning*	OTC equity ¹	North America	Other	2.5	0%
29.	Banca Farmafactoring	Listed equity	Europe	Services	1.1	0%
	Total Derived Inve	estments			288.8	32%

^{*}Denotes overlap with the Private Equity portfolio

^{1.} OTC = Over-the-counter




Adjusted NAV per share progression

Adjusted NAV per share progression (€)

	Adjusted NAV/share at the beginning of the period	Income	Realised gains	Unrealised gains	FX	Dividend	Other	Adjusted NAV/share at end of the period	Return %	Total NAV Return %	Total NAV Return % (constant currency)
1Q15 ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	8.8%		
2Q15 ¹	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-0.4%	12.60/	0.5%
3Q15	€1.79	€0.01	€0.00	-€0.01	-€0.01	€0.00	€0.00	€1.78	-0.4%	13.6%	9.5%
4Q15	€1.78	€0.01	€0.01	€0.07	€0.02	€0.00	-€0.01	€1.88	5.6%		
1Q16	€1.88	€0.02	€0.00	€0.01	-€0.06	-€0.05	-€0.00	€1.80	-1.8%		
2Q16	€1.80	€0.02	€0.00	-€0.02	€0.03	€0.00	-€0.01	€1.82	1.2%	C C0/	3.9%
3Q16	€1.82	€0.02	€0.00	€0.03	-€0.01	-€0.05	-€0.00	€1.81	2.0%	6.6%	
4Q16	€1.81	€0.02	€0.00	€0.02	€0.07	€0.00	-€0.01	€1.91	5.2%		
1Q17	€1.91	€0.02	€0.00	€0.03	-€0.01	-€0.05	-€0.01	€1.89	1.4%		
2Q17	€1.89	€0.01	€0.04	€0.01	-€0.08	€0.00	-€0.02	€1.85	-2.1%	2.20/	10.20/
3Q17	€1.85	€0.01	€0.00	€0.03	-€0.04	-€0.05	-€0.00	€1.80	-0.3%	2.2%	10.2%
4Q17	€1.80	€0.01	€0.03	€0.05	-€0.02	€0.00	-€0.01	€1.86	3.5%		
1Q18	€1.86	€0.01	€0.01	€0.00	-€0.03	-€0.05	-€0.00	€1.80	-0.7%	-0.7%	1.0%

Adjusted NAV per share progression (€)




1. PCV, AGA's predecessor before IPO on 15 June 2015




Key financial highlights at 31 March 2018

Net Asset Values per share (€/£) 1Q18 4Q17 3Q17 2Q17 1Q17 NAV per share €1.80/£1.58 €1.89/£1.68 €1.82/£1.62 €1.87/£1.64 €1.91/£1.62 Adjusted NAV per share €1.80/£1.58 €1.86/£1.65 €1.80/£1.58 €1.85/£1.62 €1.89/£1.60





Total NAV split (€m)






















Portfolio split by sector 31 March 2018




1Q17	1Q18
39%	33%
29%	31%
18%	18%
13%	16%
0%	1%
1%	1%
	39% 29% 18% 13% 0%

Portfolio split by fund exposure 31 March 2018



1Q18	1Q17	
22%	-1%	A AIX
67%	87%	B AVIII
8%	13%	C AEVII
0%	0%	D AEVI
3%	1%	E AMI
0%	0%	F ADF
		. ,,,,,,

Portfolio split by currency 31 March 2018




	1Q17	1Q18
A USD	47%	44%
B EUR	30%	38%
C GBP	1%	5%
D NOK	10%	4%
E ILS	3%	3%
F INR	5%	3%
G HKD	1%	2%
H Other	3%	1%

Portfolio split by Private Equity vintage 31 March 2018



	1Q17	1Q18
A 2005-2012	12%	8%
B 2013	15%	9%
C 2014	2%	1%
D 2015	52%	44%
E 2016	14%	15%
F 2017	5%	23%
G 2018	0%	0%


Portfolio split by geography 31 March 2018





		1Q17	1Q18
Α	North America	46%	42%
В	Europe	40%	41%
С	United Kingdom	1%	5%
D	Israel	4%	5%
Ε	India	7%	4%
F	China	1%	2%
G	Rest of World	1%	1%




Portfolio composition - Derived Investments













Portfolio composition - Derived Debt Investments







Endnotes



References to "Apax Funds"

Private Equity Funds advised by Apax Partners LLP to which AGA is committed are Apax IX - consisting of a euro tranche ("AIX – EUR") and a US dollar tranche ("AIX – USD"), Apax Digital Fund ("ADF"), AMI Opportunities Fund ("AMI"), Apax VIII ("AVIII") – consisting of a euro tranche ("AVIII – EUR") and a US Dollar tranche ("AVIIII – USD"), Apax Europe VI ("AEVII"). In addition, reference is made to the Apax Buyout Funds which includes AIX, AVIII, AEVII, Apax US VII, L.P. ("USVII"), AEVI and Apax Europe V ("AEV"). Please note that throughout this presentation both the funds full name and abbreviated forms are used interchangeably.

Information with Respect to AGA Performance including Gross IRRs, Net IRRs and MOICs

"Gross IRR" as used throughout this Presentation, and unless otherwise indicated, means an aggregate, annual, compound, gross internal rate of return calculated on the basis of cash receipts and payments together with the valuation of unrealised investments at the measurement date. Foreign currency cash flows have been converted at the exchange rates applicable at the date of receipt or payment by the relevant entity.

For the Company's Private Equity Investments, Gross IRR is net of fees and carried interest paid to the underlying investment manager and/or general partner of the relevant fund. For Derived Investments, Gross IRR does not reflect expenses to be borne by the relevant investment vehicle or its investors including, without limitation, performance fees, management fees, taxes and organisational, partnership or transaction expenses. "Net IRR" means Gross IRR less any expenses borne by the relevant investment vehicle or its investors including, without limitation, carried interest, management fees, taxes and organisational or transaction expenses. Please note that Multiples of Invested Capital ("MOICs) are presented in this Presentation on the basis indicated.

In certain instances, the Gross IRR shown is a concurrent IRR, meaning a gross annual IRR, calculated as if the first cash flow associated with all investments started in the same month.

